Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study

Overview of attention for article published in Drug Design, Development and Therapy, May 2015

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 2 public wall posts from 2 users.

A JAK2(V617F) mutation is found in approximately 55% of patients with essential thrombocythemia (ET), and represents a key…

[Abstract] "Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an…